Therapeutic potential of targeting mirnas to prostate cancer tumors: using psma as an active target

References

• Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, et al. Prostate cancer. Journal of the National Comprehensive Cancer Network. 2010;8(2):162–10. doi:10.6004/jnccn.2010.0012.
   PubMed Web of Science ®Google Scholar
• Whitburn J, Rao SR, Morris EV, Tabata S, Hirayama A, Soga T, Edwards JR, Kaya Z, Palmer C, Hamdy FC, et al. Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. Sci Adv. 2022;8(8):eabf9096. doi:10.1126/sciadv.abf9096.
   PubMed Web of Science ®Google Scholar
• Alibhai SMH, Breunis H, Feng G, Timilshina N, Hansen A, Warde P, Gregg R, Joshua A, Fleshner N, Tomlinson G, et al. Association of chemotherapy, enzalutamide, abiraterone, and radium 223 with cognitive function in older men with metastatic castration-resistant prostate cancer. JAMA Netw Open. 2021;4(7):e2114694. doi:10.1001/jamanetworkopen.2021.14694.
   PubMed Web of Science ®Google Scholar
• McAllister MJ, Underwood MA, Leung HY, Edwards J. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Transl Res. 2019;206:91–106. doi:10.1016/j.trsl.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Pal SK, Twardowski P, Sartor O. Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging. 2010;5:395–402. doi:10.2147/CIA.S14570.
   PubMed Web of Science ®Google Scholar
• Cereda V, Formica V, Massimiani G, Tosetto L, Roselli M. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. Expert Opin Investig Drugs. 2014;23(4):469–487. doi:10.1517/13543784.2014.885950.
   PubMed Web of Science ®Google Scholar
• Erdmann K, Kaulke K, Thomae C, Huebner D, Sergon M, Froehner M, Wirth MP, Fuessel S. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRnas. BMC Cancer. 2014;14(1):1–14. doi:10.1186/1471-2407-14-82.
   PubMed Web of Science ®Google Scholar
• Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost A-K, Weigle B, Kiessling A, Wirth MPet al. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol. 2003;23:221–228. doi:10.3892/ijo.23.1.221.
   PubMed Web of Science ®Google Scholar
• Caromile LA, Shapiro LH. PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Molecular & Cellular Oncology. 2017;4:e1321168. doi:10.1080/23723556.2017.1321168.
   PubMed Web of Science ®Google Scholar
• Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445–1451.
   PubMed Web of Science ®Google Scholar
• Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A. 1996;93:749–753. doi:10.1073/pnas.93.2.749.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–539. doi:10.1002/jcb.10661.
   PubMed Web of Science ®Google Scholar
• Murphy GP, Su S, Jarisch J, Kenny GM. Serum levels of PSMA. The Prostate. 2000;42:318–319. doi:10.1002/(SICI)1097-0045(20000301)42:4<318:AID-PROS10>3.0.CO. 2-L [pii].
   PubMed Web of Science ®Google Scholar
• Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome. 2001;12(2):117–123. doi:10.1007/s003350010240.
   PubMed Web of Science ®Google Scholar
• Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol. 2005;288(5):C975–981. doi:10.1152/ajpcell.00506.2004.
   PubMed Web of Science ®Google Scholar
• Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055–4060.
   PubMed Web of Science ®Google Scholar
• Li S, Luo W. Matrix metalloproteinase 2 contributes to aggressive phenotype, epithelial-mesenchymal transition and poor outcome in nasopharyngeal carcinoma. Onco Targets Ther. 2019;12:5701. doi:10.2147/OTT.S202280.
   PubMed Web of Science ®Google Scholar
• Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JDM, Franssen GM, Groningen MCCV, Schottelius M, Wester H-J, van Weerden WM, Boerman OC, et al. Towards personalized treatment of prostate cancer: pSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics. 2016;6(6):849–861. doi:10.7150/thno.14744.
   PubMed Web of Science ®Google Scholar
• Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, et al. A high-affinity [18F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015;42(10):780–787. doi:10.1016/j.nucmedbio.2015.06.003.
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (psma) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1):9–15. doi:10.1158/1078-0432.ccr-15-0820.
   PubMed Web of Science ®Google Scholar
• Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, Anderson CJ, Berkman CE. 177lu-labeled phosphoramidate-based psma inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics. 2017;7(7):1928–1939. doi:10.7150/thno.18719.
   PubMed Web of Science ®Google Scholar
• Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, Salamacha N, Shen D, Geruntho JJ, Rigatti LH, et al. Preclinical dosimetry, imaging, and targeted radionuclide therapy studies of lu-177-labeled albumin-binding, psma-targeted CTT1403. Mol Imaging Biol. 2019;22(2):274–284. doi:10.1007/s11307-019-01404-8.
   Web of Science ®Google Scholar
• Nedrow-Byers JR, Moore AL, Ganguly T, Hopkins MR, Fulton MD, Benny PD, Berkman CE. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. The Prostate. 2013;73(4):355–362. doi:10.1002/pros.22575.
   PubMed Web of Science ®Google Scholar
• Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. The Prostate. 2012;72(8):904–912. doi:10.1002/pros.21493.
   PubMed Web of Science ®Google Scholar
• Liu T, Wu LY, Kazak M, Berkman CE. Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. The Prostate. 2008;68:955–964. doi:10.1002/pros.20753.
   PubMed Web of Science ®Google Scholar
• Choy CJ, Geruntho JJ, Davis AL, Berkman CE. Tunable pH-sensitive linker for controlled release. Bioconjug Chem. 2016;27:824–830. doi:10.1021/acs.bioconjchem.6b00027.
   PubMed Web of Science ®Google Scholar
• Choy CJ, Ley CR, Davis AL, Backer BS, Geruntho JJ, Clowers BH, Berkman CE. Second-generation tunable ph-sensitive phosphoramidate-based linkers for controlled release. Bioconjug Chem. 2016;27(9):2206–2213. doi:10.1021/acs.bioconjchem.6b00422.
   PubMed Web of Science ®Google Scholar
• Dassie JP, et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.
   Google Scholar
• Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, Hidalgo-Miranda A. miRNA biogenesis: biological impact in the development of cancer. Cancer Biology & Therapy. 2014;15:1444–1455. doi:10.4161/15384047.2014.955442.
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences. 2006;103(7):2257–2261. doi:10.1073/pnas.0510565103.
   PubMed Web of Science ®Google Scholar
• Borralho PM, Simões AES, Gomes SE, Lima RT, Carvalho T, Ferreira DMS, Vasconcelos MH, Castro RE, Rodrigues CMP. miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PloS One. 2011;6(8):e23787. doi:10.1371/journal.pone.0023787.
   PubMed Web of Science ®Google Scholar
• Gambari R, Brognara E, Spandidos DA, Fabbri E. Targeting oncomiRnas and mimicking tumor suppressor miRnas: new trends in the development of miRNA therapeutic strategies in oncology. Int J Oncol. 2016;49(1):5–32. doi:10.3892/ijo.2016.3503.
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRnas in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775–789. doi:10.1038/nrd3179.
   PubMed Web of Science ®Google Scholar
• Yarahmadi A, Shahrokhi SZ, Mostafavi-Pour Z, Azarpira N. MicroRnas in diabetic nephropathy: from molecular mechanisms to new therapeutic targets of treatment. Biochem Pharmacol. 2021;189:114301. doi:10.1016/j.bcp.2020.114301.
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev. 2015;81:142–160. doi:10.1016/j.addr.2014.10.031.
   PubMed Web of Science ®Google Scholar
• Bader A, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRnas for cancer. Gene Ther. 2011;18:1121–1126. doi:10.1038/gt.2011.79.
   PubMed Web of Science ®Google Scholar
• Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRnas in prostate cancer. Clin Transl Oncol. 2019;21:126–144. doi:10.1007/s12094-018-1910-8.
   PubMed Web of Science ®Google Scholar
• Chen W-Y, Liu S-Y, Chang Y-S, Juan Yin J, Yeh H-L, Mouhieddine TH, Hadadeh O, Abou-Kheir W, Liu Y-N. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in ras-activated prostate cancer. Oncotarget. 2015;6(1):441. doi:10.18632/oncotarget.2690.
   PubMedGoogle Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi:10.1016/0092-8674(93)90529-y.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Han J, Yeom K-H, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. Embo J. 2004;23(20):4051–4060. doi:10.1038/sj.emboj.7600385.
   PubMed Web of Science ®Google Scholar
• Han J, Lee Y, Yeom K-H, Kim Y-K, Jin H, Kim VN. The drosha-DGCR8 complex in primary microRNA processing. Genes & Development. 2004;18(24):3016–3027. doi:10.1101/gad.1262504.
   PubMed Web of Science ®Google Scholar
• Guo Z, Li B, Tian P, Li D, Zhang Y, Li Q, Fan T, Yue J, Guo Y. DGCR8 expression is altered in children with congenital heart defects. Clinica Chimica Acta. 2019;495:25–28. doi:10.1016/j.cca.2019.03.1619.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by exportin 5. Nucleic Acids Res. 2004;32(16):4776–4785. doi:10.1093/nar/gkh824.
   PubMed Web of Science ®Google Scholar
• Flores-Jasso CF, Arenas-Huertero C, Reyes JL, Contreras-Cubas C, Covarrubias A, Vaca L. First step in pre-miRnas processing by human dicer. Acta Pharmacol Sin. 2009;30(8):1177–1185. doi:10.1038/aps.2009.108.
   PubMed Web of Science ®Google Scholar
• Yoda M, Kawamata T, Paroo Z, Ye X, Iwasaki S, Liu Q, Tomari Y. ATP-dependent human RISC assembly pathways. Nature Structural & Molecular Biology. 2010;17(1):17–23. doi:10.1038/nsmb.1733.
   PubMed Web of Science ®Google Scholar
• Meijer HA, Smith EM, Bushell M. Regulation of miRNA strand selection: follow the leader? Biochem Soc Trans. 2014;42:1135–1140. doi:10.1042/BST20140142.
   PubMed Web of Science ®Google Scholar
• Cochetti G. Role of miRNAs in prostate cancer: Do we really know everything? Urologic oncology: seminars and original investigations. 2020 Jul;38(7):623–635. doi:10.1016/jurolonc.2020.03.007. PubMed ID: 32284256.
   Web of Science ®Google Scholar
• Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT, Califano J, Wu T-C, Pang X. Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prevention Research. 2011;4(7):1073–1083. doi:10.1158/1940-6207.CAPR-10-0333.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shao S, Pan H, Cheng Z, Rui X. MicroRNA‑136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen‑activated protein kinase kinase 4. Mol Med Rep. 2018;17:4803–4810. doi:10.3892/mmr.2018.8417.
   PubMed Web of Science ®Google Scholar
• Liu C-Y, Su S-H, Chang T-H, Hsieh M-L, Chang Y-H, Pang JST, Chuang C-K. Promoter gene methylation regulates clooxygenase-2 expression in androgen-dependent and independent prostate cancer cells. World J Oncol. 2022;13(3):107–116. doi:10.14740/wjon1478.
   PubMedGoogle Scholar
• Shen T, Wang W, Zhou W, Coleman I, Cai Q, Dong B, Ittmann MM, Creighton CJ, Bian Y, Meng Y, et al. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. J Clin Invest. 2021;131(4). doi:10.1172/JCI135465.
   Web of Science ®Google Scholar
• Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomedicine & Pharmacotherapy. 2019;114:108800. doi:10.1016/j.biopha.2019.108800.
   PubMed Web of Science ®Google Scholar
• Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG. microRNA, cell cycle, and human breast cancer. Am J Pathol. 2010;176(3):1058–1064. doi:10.2353/ajpath.2010.090664.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu X, Xu X, Li S, Liang Z, Hu Z, Wu J, Zhu Y, Jin X, Wang X, et al. MicroRna‑193a‑3p inhibits cell proliferation in prostate cancer by targeting cyclin D1. Oncol Lett. 2017;14:5121–5128. doi:10.3892/ol.2017.6865.
   PubMed Web of Science ®Google Scholar
• Ma Z, Luo Y, Qiu M. miR-143 induces the apoptosis of prostate cancer LNCap cells by suppressing Bcl-2 expression. Medical Science Monitor: international Medical Journal of Experimental and Clinical Research. 2017;23:359. doi:10.12659/MSM.899719.
   PubMed Web of Science ®Google Scholar
• Ostadrahimi S, Fayaz S, Parvizhamidi M, Abedi‑valugerdi M, Hassan M, Kadivar M, Teimoori‑toolabi L, Asgari M, Shahrokh H, Abolhasani M, et al. Downregulation of miR‑1266‑5P, miR‑185‑5P and miR‑30c‑2 in prostatic cancer tissue and cell lines. Oncol Lett. 2018;15:8157–8164. doi:10.3892/ol.2018.8336.
   PubMed Web of Science ®Google Scholar
• Derynck R, Weinberg RA. EMT and cancer: more than meets the eye. Dev Cell. 2019;49:313–316. doi:10.1016/j.devcel.2019.04.026.
   PubMed Web of Science ®Google Scholar
• Zaravinos A. The regulatory role of microRnas in EMT and cancer. J Oncol. 2015;2015. doi:10.1155/2015/865816.
   Web of Science ®Google Scholar
• Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14:481–487. doi:10.1080/15384101.2015.1006048.
   PubMed Web of Science ®Google Scholar
• Li H. The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood, the Journal of the American Society of Hematology. 2017;129(4):497–508. doi:10.1182/blood-2016-05-714493.
   Google Scholar
• Fardi M, Alivand M, Baradaran B, Farshdousti Hagh M, Solali S. The crucial role of ZEB2: from development to epithelial‐to‐mesenchymal transition and cancer complexity. J Cell Physiol. 2019;234:14783–14799. doi:10.1002/jcp.28277.
   Web of Science ®Google Scholar
• Sommariva M, Gagliano N. E-cadherin in pancreatic ductal adenocarcinoma: a multifaceted actor during EMT. Cells. 2020;9:1040. doi:10.3390/cells9041040.
   PubMed Web of Science ®Google Scholar
• Yu J, LU Y, CUI DI, LI E, ZHU Y, ZHAO Y, ZHAO F, XIA S. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncol Rep. 2014;31(2):910–918. doi:10.3892/or.2013.2897.
   PubMed Web of Science ®Google Scholar
• Scott LE, Weinberg SH, Lemmon CA. Mechanochemical signaling of the extracellular matrix in epithelial-mesenchymal transition. Frontiers in Cell and Developmental Biology. 2019;7:135. doi:10.3389/fcell.2019.00135.
   PubMed Web of Science ®Google Scholar
• Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129:1375–1383. doi:10.1053/j.gastro.2005.09.055.
   PubMed Web of Science ®Google Scholar
• Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, et al. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death & Differentiation. 2012;19(11):1750–1760. doi:10.1038/cdd.2012.56.
   PubMed Web of Science ®Google Scholar
• Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin. 1989;39(6):376–393. doi:10.3322/canjclin.39.6.376.
   PubMed Web of Science ®Google Scholar
• Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86(10):1566–1577. doi:10.1038/sj.bjc.6600315.
   PubMed Web of Science ®Google Scholar
• Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005;46:481–489. doi:10.1111/j.1365-2559.2005.02142.x.
   PubMed Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135. doi:10.1016/j.addr.2010.03.011.
   PubMed Web of Science ®Google Scholar
• Au J-S, Yeung BZ, Wientjes MG, Lu Z, Wientjes MG. Delivery of cancer therapeutics to extracellular and intracellular targets: determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev. 2016;97:280–301. doi:10.1016/j.addr.2015.12.002.
   PubMed Web of Science ®Google Scholar
• Craig V, Tzankov A, Flori M, Schmid CA, Bader AG, Müller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 2012;26(11):2421–2424. doi:10.1038/leu.2012.110.
   PubMed Web of Science ®Google Scholar
• Zang X, Zhang X, Zhao X, Hu H, Qiao M, Deng Y, Chen D. Targeted delivery of miRNA 155 to tumor associated macrophages for tumor immunotherapy. Mol Pharm. 2019;16(4):1714–1722. doi:10.1021/acs.molpharmaceut.9b00065.
   PubMedGoogle Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31. doi:10.1038/nm0195-27.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. doi:10.1038/35025220.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. Journal of Experimental & Clinical Cancer Research. 2019;38:1–13.
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58–65. doi:10.1038/scientificamerican0794-58.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi:10.1016/j.addr.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20. doi:10.1021/nn900002m.
   PubMed Web of Science ®Google Scholar
• Bae YH. Drug targeting and tumor heterogeneity. J Control Release. 2009;133(1). doi:10.1016/j.jconrel.2008.09.074.
   Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRnas in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–469. doi:10.1016/j.molmed.2014.06.005.
   PubMed Web of Science ®Google Scholar
• Caromile LA, Dortche K, Rahman MM, Grant CL, Stoddard C, Ferrer FA, Shapiro LH. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal. 2017;10(470). doi:10.1126/scisignal.aag3326.
   PubMed Web of Science ®Google Scholar
• Nguyen DP, Xiong PL, Liu H, Pan S, Leconet W, Navarro V, Guo M, Moy J, Kim S, Ramirez-Fort MK, et al. Induction of PSMA and internalization of an anti-PSMA mAb in the vascular compartment. Mol Cancer Res. 2016;14(11):1045–1053. doi:10.1158/1541-7786.MCR-16-0193.
   PubMed Web of Science ®Google Scholar
• Singh S, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009;16(5):645–659. doi:10.1038/gt.2008.185.
   PubMed Web of Science ®Google Scholar
• Jin W, Qin B, Chen Z, Liu H, Barve A, Cheng K. Discovery of PSMA-specific peptide ligands for targeted drug delivery. Int J Pharm. 2016;513(1–2):138–147. doi:10.1016/j.ijpharm.2016.08.048.
   PubMedGoogle Scholar
• Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181:151–167. doi:10.1016/j.cell.2020.02.001.
   PubMed Web of Science ®Google Scholar
• Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody–chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004;64(21):7995–8001. doi:10.1158/0008-5472.CAN-04-1722.
   PubMed Web of Science ®Google Scholar
• Rege K, Patel SJ, Megeed Z, Yarmush ML. Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer Res. 2007;67:6368–6375. doi:10.1158/0008-5472.CAN-06-3658.
   PubMed Web of Science ®Google Scholar
• Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Šácha P, Konvalinka J. Comparative analysis of monoclonal antibodies against prostate‐specific membrane antigen (PSMA). The Prostate. 2014;74(16):1674–1690. doi:10.1002/pros.22887.
   PubMed Web of Science ®Google Scholar
• Behe M, Alt K, Deininger F, Bühler P, Wetterauer U, Weber WA, Elsässer-Beile U, Wolf P. In vivo testing of 177lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. In Vivo. 2011;25:55–59.
   PubMed Web of Science ®Google Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nature reviews Drug discovery. 2010;9:537–550. doi:10.1038/nrd3141.
   Google Scholar
• Kruspe S, Mittelberger F, Szameit K, Hahn U. Aptamers as drug delivery vehicles. ChemMedchem. 2014;9:1998–2011. doi:10.1002/cmdc.201402163.
   PubMed Web of Science ®Google Scholar
• Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V et al. Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Molecular Therapy. 2014;22(6):1151–1163. doi:10.1038/mt.2014.5.
   PubMed Web of Science ®Google Scholar
• Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez FJ, Liu XY, Wilson ME, et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Molecular Therapy. 2014;22(11):1910–1922. doi:10.1038/mt.2014.117.
   PubMed Web of Science ®Google Scholar
• Wu X . Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomedicine. 2011;6:1747. doi:10.2147/IJN.S23747.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhang L, Dai Y, Wang Z, Li C, Peng Y, Ma D, He P. PSMA-Targeting reduction-cleavable hyperbranched polyamide-amine gene delivery system to treat the bone metastases of prostate cancer. molecular Therapy. 2020;15:7173. doi:10.2147/IJN.S268398.
   Google Scholar
• Mehlhorn H. 2016. Nanoparticles in the fight against parasites. In: Melhorn H, editor. Parasitology Research MonographsSwitzerland. 1st ed. pp. 1–14. Springer Cham: Nanoparticles - Definitions. doi: 10.1007/978-3-319-25292-6.
   Google Scholar
• Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011;28:237–259. doi:10.1007/s11095-010-0318-0.
   PubMed Web of Science ®Google Scholar
• Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion JP. Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles? Chemical Science. 2019;10(35):8119–8128. doi:10.1039/C9SC02290B.
   PubMed Web of Science ®Google Scholar
• Binzel DW, Shu Y, Li H, Sun M, Zhang Q, Shu D, Guo B, Guo P. Specific delivery of miRNA for high efficient inhibition of prostate cancer by RNA nanotechnology. Molecular Therapy. 2016;24(7):1267–1277. doi:10.1038/mt.2016.85.
   PubMed Web of Science ®Google Scholar
• Saniee F, Shabani Ravari N, Goodarzi N, Amini M, Atyabi F, Saeedian Moghadam E, Dinarvand R. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel. Pharm Dev Technol. 2021;26(4):381–389. doi:10.1080/10837450.2021.1875238.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao D-Y, Huang L. In vivo delivery of miRnas for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–141. doi:10.1016/j.addr.2014.05.009.
   PubMed Web of Science ®Google Scholar
• Segal M, Slack F. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opinion on Drug Discovery. 2020;15(9):987–991. doi:10.1080/17460441.2020.1765770.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, Welsh J, Calin GA. Role of miRnas in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244–253. doi:10.1002/gcc.22725.
   PubMed Web of Science ®Google Scholar
• Curtale G. MiRnas at the crossroads between innate immunity and cancer: focus on macrophages. Cells. 2018;7(12). doi:10.3390/cells7020012.
   PubMedGoogle Scholar
• Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18:282–289. doi:10.1016/j.drudis.2012.10.002.
   PubMed Web of Science ®Google Scholar
• Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Seminars in cancer biology. 2008;18(2):89–102. doi:10.1016/j.semcancer.2008.01.004.
   PubMed Web of Science ®Google Scholar
• Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34:2294–2304. doi:10.1093/nar/gkl183.
   PubMed Web of Science ®Google Scholar
• Sharma C, Awasthi SK. Versatility of peptide nucleic acids (PNA s): role in chemical biology, drug discovery, and origins of life. Chemical Biology & Drug Design. 2017;89:16–37. doi:10.1111/cbdd.12833.
   PubMed Web of Science ®Google Scholar
• Lima JF, Cerqueira L, Figueiredo C, Oliveira C, Azevedo NF. Anti-miRNA oligonucleotides: a comprehensive guide for design. RNA Biol. 2018;15:338–352. doi:10.1080/15476286.2018.1445959.
   PubMed Web of Science ®Google Scholar
• Schachner-Nedherer A-L, Werzer O, Kornmueller K, Prassl R, Zimmer A. Biological activity of miRNA-27a using peptide-based drug delivery systems. Int J Nanomedicine. 2019;14:7795. doi:10.2147/IJN.S208446.
   PubMed Web of Science ®Google Scholar
• Zou L-L, Ma J-L, Wang T, Yang T-B, Liu C-B. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Chemical Biology & Drug Design. 2013;11(2):197–208. doi:10.2174/1570159X11311020006.
   Google Scholar
• Fabani MM, Gait MJ. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates. Rna. 2008;14:336–346. doi:10.1261/rna.844108.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Abdelaal AM, Rangasamy L, Tenneti S, Myoung S, Low PS, Kasinski AL. Enhancing microRNA activity through increased endosomal release mediated by nigericin. Molecular Therapy-Nucleic Acids. 2019;16:505–518. doi:10.1016/j.omtn.2019.04.003.
   Web of Science ®Google Scholar
• Xie Y, Yu F, Tang W, Alade BO, Peng Z-H, Wang Y, Li J, Oupický D. Chloroquine-containing DMAEMA copolymers as efficient anti-miRNA delivery vectors with improved endosomal escape and anti-migratory activity in cancer cells. Macromol Biosci. 2018;18(1). doi:10.1002/mabi.201700194.
   Web of Science ®Google Scholar
• Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10(24):4256–4271. doi:10.4161/cc.10.24.18552.
   PubMed Web of Science ®Google Scholar
• Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, Tang DG. microRNA-34A: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. 2021;9:640587. doi:10.3389/fcell.2021.640587.
   PubMed Web of Science ®Google Scholar
• Tong A, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther. 2008;15:341–355. doi:10.1038/cgt.2008.8.
   PubMed Web of Science ®Google Scholar
• Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272–283. doi:10.1038/nrg.2016.20.
   PubMed Web of Science ®Google Scholar
• Fernandez-Piñeiro I, Badiola I, Sanchez A. Nanocarriers for microRNA delivery in cancer medicine. Biotechnol Adv. 2017;35:350–360. doi:10.1016/j.biotechadv.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Conde J, Artzi N. Are RNAi and miRNA therapeutics truly dead? Trends Biotechnol. 2015;33:141–144. doi:10.1016/j.tibtech.2014.12.005.
   PubMed Web of Science ®Google Scholar
• Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, Jaggi M. miRNA nanotherapeutics for cancer. Drug Discov Today. 2017;22(2):424–432. doi:10.1016/j.drudis.2016.10.014.
   PubMed Web of Science ®Google Scholar